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Abstract
Purpose The study serves to optimise conditions for multi-
pinhole SPECT small animal imaging of 123I- and 99mTc-
labelled radiopharmaceuticals with different distributions in
murine heart and brain and to investigate detection and
dose range thresholds for verification of differences in
tracer uptake.
Methods A Triad 88/Trionix system with three 6-pinhole
collimators was used for investigation of dose requirements
for imaging of the dopamine D2 receptor ligand [
123I]IBZM
and the cerebral perfusion tracer [99mTc]HMPAO (1.2–
0.4 MBq/g body weight) in healthy mice. The fatty acid
[123I]IPPA (0.94±0.05 MBq/g body weight) and the
perfusion tracer [99mTc]sestamibi (3.8±0.45 MBq/g body
weight) were applied to cardiomyopathic mice overexpress-
ing the prostaglandin EP3 receptor.
Results In vivo imaging and in vitro data revealed 45 kBq
total cerebral uptake and 201 kBq cardiac uptake as thresholds
for visualisation of striatal [123I]IBZM and of cardiac [99mTc]
sestamibi using 100 and 150 s acquisition time, respectively.
Alterations of maximal cerebral uptake of [123I]IBZM by
>20% (116 kBq) were verified with the prerequisite of 50%
striatal of total uptake. The labelling with [99mTc]sestamibi
revealed a 30% lower uptake in cardiomyopathic hearts
compared to wild types. [123I]IPPA uptake could be
visualised at activity doses of 0.8 MBq/g body weight.
Conclusion Multi-pinhole SPECT enables detection of alter-
ations of the cerebral uptake of 123I- and 99mTc-labelled tracers
in an appropriate dose range in murine models targeting
physiological processes in brain and heart. The thresholds of
detection for differences in the tracer uptake determined under
the conditions of our experiments well reflect distinctions in
molar activity and uptake characteristics of the tracers.
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During the last decade multi-pinhole SPECT systems of
various designs have been proposed for use in preclinical
research and also for some clinical applications [1–9].
Multi-pinhole designs for SPECT applications range from
systems with a few detectors using collimators with a large
number of pinholes, which do not reduce the counting rate
substantially and allow for high time resolution, to systems
with several detectors using collimators with only a few
pinholes, or alternatively, annular detectors, with emphasis
on improvement of the spatial resolution. Clinical applica-
tions of such systems have been proposed for the
assessment of alterations due to hyperplastic parathyroid
glands [7, 10] and for diagnosis of rheumatism, arthrosis
[5] and coronary heart disease [8].
In preclinical research, multi-pinhole SPECT is devel-
oping into a complement to PET as a tool for in vivo
imaging of pharmacodynamics and pharmacokinetics of
receptor ligands [11], tracers of metabolic processes [12,
13] and physiological properties in healthy and diseased
small animals [3, 14–17]. Dedicated SPECT and PET
systems can provide sufficient spatial and temporal resolu-
tion for quantitative observation of such processes even in
mouse models.
The high availability of SPECT radiopharmaceuticals,
increasing experience with SPECT tracers in small animal
imaging [3, 4, 13, 18–22] and improvement of resolution
parameters of SPECT with multi-pinhole devices contribute
to broadening the role that multi-pinhole SPECT (MPS) is
able to play in small animal imaging. The use of a broad
range of tracers is especially important for the study of
transgenic mouse models, which have become an essential
tool of biological research during the last two decades.
Due to the high variety of gamma cameras applied to
small animal imaging, reproducibility of experiments
requires a detailed description of the visualisation con-
ditions used for different tracers, requirements of tracer
dose and technical parameters of the SPECT devices,
sensitivity as well as geometric properties of the animal
model investigated [4, 23, 24].
The present study focuses on the evaluation of the
parameters required for the imaging of mouse brains and
hearts using different tracers and animal models and a MPS
including three 6-pinhole collimators. To this aim, the
definition of the dose range for different tracers and the
quantitative assessment of detection borders of anatomical
and molecular alterations were performed in physiological
and pathophysiological mouse models by means of the
MPS. We investigated the biodistribution of the dopamine
D2 receptor ligand [
123I]IBZM and the flow tracer [99mTc]
HMPAO in the brains of normal NMRI mice. The tracers
are both widely used in experimental and clinical applica-
tions for the evaluation of dopaminergic signal transduction
[25–28] and cerebral perfusion. Another set of tracers, the
long chain fatty acid [123I]IPPA and the flow tracer [99mTc]
sestamibi, were applied to B6C3F1-Tg(EP3) mice with
overexpression of the prostaglandin EP3 receptor and to
wild-type littermates [29]. Although the prostaglandin EP3
receptor is known to mediate cardiac protection during
ischaemia and reperfusion, the development of cardiac
hypertrophy has been observed in these animals. The recent
investigations contribute to the further characterisation of
the physiological and metabolic phenotype of these hearts
on the one hand as well as to the estimation of the borders
of detection of alterations in the uptake of radiopharma-
ceuticals in normal tissues and under pathophysiological
conditions on the other hand. Two data processing tools are
compared for their abilities in assessment of the SPECT
imaging data. Localisation of anatomical structures and
assessment of alterations in their size is supported by MR
imaging of brain and heart.
Materials and methods
Chemicals
Ketamine and xylazine were purchased from Sigma–
Aldrich (Deisenhofen, Germany), [123I]IBZM (iolopride;
[123I](S)-2-hydroxy-3-iodo-6-methoxy-N-[(1-ethyl-2-pyrro-
lidinyl-9-methyl)]-benzamide; specific activity: >74 TBq/
mmol) and [99mTc]HMPAO ([99mTc]-(D, L)-hexa-methyl-
propylene-amine oxime; Ceretec preparation kit) from
Amersham Buchler (Braunschweig, Germany), [99mTc]-2-
methoxy-iodobutyl-isonitrile (Cardiolite) preparation kit
was supplied by Bristol-Myers Squibb and [123I]IPPA
(para-iodo-phenyl-pentadecanoic acid; specific activity:
185–460 GBq/mmol) has been synthesised by Dr. Peter
van Doremalen (Eindhoven, The Netherlands).
For the SPECT measurements a Triad 88 system
upgraded with 6-pinhole collimators with an average
sensitivity of 835 cps/MBq and an inner diameter of
1.5 mm was used as described previously [2, 30].
Animals
All animals were obtained from Charles River Deutschland
GmbH (Sulzfeld, Germany) (NMRI mice) or the Animal
Care Unit of the Heinrich Heine University Düsseldorf
[B6C3F1-Tg(EP3)].
Mice with cardiac-specific overexpression of the porcine
homologue of the human Gi/Gq-coupled EP3II receptor
subtype under control of the α-myosin heavy chain (α-
MHC) promoter were generated using standard techniques
as described previously [29].
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The animals were kept at 12/12-h dark-light cycles. All
procedures were performed in accordance with the
German Guidelines for Care and Use of Laboratory
Animals and approved by the governmental Animal
Research Committee.
General experimental procedure
The investigations were performed in 24 animals (7 NMRI:
34–50 g body weight; 17 B6C3F1(EP3), 7 transgenic, 10
wild-type; 18–30 g). For the SPECT experiments and for
brain MRI the mice were anaesthetised using ketamine/
xylazine (i.p. application of 100 mg/10 mg per 100 g body
weight and hour). Anaesthesia was started 15 min before
injection of the radiopharmaceuticals. For the SPECT
investigations a plastic v-notch was placed in the mouth
approximately 5 min after start of anaesthesia to ensure that
obstruction of the upper respiratory tract was avoided.
All radiopharmaceuticals were injected via the tail vein.
For the brain SPECT the mice were placed in prone
position and for the cardiac SPECT in supine position in an
animal bed in the centre of the multi-pinhole SPECT
system. At the end of the observation period the brains and
11 of the hearts were excised and the activity was measured
immediately by means of an Activimeter Isomed 1000
(Version 2.30, Nuklear-Medizintechnik Dresden GmbH,
Dresden, Germany). Subsequently, the excised organs were
scanned ex vivo (four brains and four [99mTc]-sestamibi
labelled hearts) by means of the MPS camera system with
the same acquisition time as used for the last in vivo
measurement.
The anaesthesia during MRI of the brain was the same as
for the SPECT investigations. For cardiac MRI the animals
were anaesthetised with 1.5% isoflurane in a gas mixture of
30% oxygen in nitrogen.
Brain SPECT
Cerebral uptake of [123I]IBZM and [99mTc]HMPAO was
investigated in six NMRI mice. Four animals were given
i.v. doses of 0.44, 0.56, 0.61 and 0.95 MBq [123I]IBZM/g
body weight and two other mice 0.47 and 1.16 MBq
[99mTc]HMPAO/g body weight. Measurements of [123I]
IBZM uptake started 15 min after tracer injection and
continued during eight acquisition periods. Acquisition
time was 100 s using 10 steps of rotation. After the end
of the last acquisition period the brains were dissected from
the skulls and the activity determined using the activimeter.
The excised brains were imaged with SPECT using the
same acquisition time as used for in vivo measurements.
MPS measurement of [99mTc]HMPAO was performed
using 140 s acquisition time and 10 steps of rotation
starting 75 min post-injection (p.i.).
Heart SPECT
Cardiac uptake of [99mTc]sestamibi or [123I]IPPA was
investigated in 15 male (n=3)/female (n=12) mice (trans-
genic: 6, wild-type: 9). For measurement of [99mTc]
sestamibi the tracer was injected in doses of 3.8±
0.39 MBq/g body weight. The imaging of [99mTc]sestamibi
was performed using 150 s acquisition time starting 15 min
p.i. [123I]IPPA uptake was observed after application of
0.94±0.05 MBq/g body weight with 100 s acquisition time
and 10 steps of rotation without gating starting 3 min p.i.
Reconstruction and quantification
The reconstruction of the images was performed using
HISPECT multi-pinhole reconstruction software (Scivis
GmbH , Göttingen, Germany). Quantification of the
activity accumulated in volumes of interest and regions of
interest (ROI), respectively, was performed with Vinci
2.3.1. [31] and InVivoScope processing tools (courtesy of
Dr. Christian Lackas) as described previously [32]. Stan-
dard uptake values (SUV) were calculated according to the
equation: SUV = activity per g target tissue/activity applied
per animal * g body weight [33, 34]. The segmental
evaluation of the cardiac distribution of [99mTc]sestamibi
was performed choosing the ROIs as described previously
[35]. The quantification of cardiac uptake using the
InVivoScope processing tool was performed by determina-
tion of the sum of intensity signals within the whole heart.
In contrast, the calculation of the intensity by means of the
Vinci processing tool was performed by determination of
the intensities measured in the wall of the left ventricle in
short axis view, horizontal long axis view and vertical long
axis view and evaluation of the total intensity in the
apparent volume of the left ventricle using these data.
MR imaging of brain and heart
MR brain imaging was performed using a 9.4 T animal
scanner based on a horizontal superconducting magnet
(Magnex, Scientific Ltd., Yarnton, UK) with a bore size of
16 cm equipped with a 10-cm inner diameter gradient coil
and a gradient strength of 270 mT/m [30]. A 20-mm
surface coil was used for both excitation and signal
detection.
Cardiac MR imaging was performed using a vertical
Bruker DRX 9.4 T NMR spectrometer, with a 40-mm
gradient set (maximum strength 1 T/m) and a 30-mm
birdcage resonator. The images were acquired using an
ECG- and respiration-gated gradient echo cine sequence
(repetition time of 5 ms, echo time 2.5 ms, flip angle 15°,
field of view 30×30 mm2, reconstruction matrix site 256×
256, slice thickness = 1 mm).
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Statistical analysis
Results are expressed as mean ± standard error of mean
(SEM). Significance of differences between several groups
were identified using one-way analysis of variance
(ANOVA) followed by the Student-Newman-Keuls test
for multiple comparison. Comparison between two groups
was performed using a paired and an unpaired Student’s t
test. Pearson’s coefficient was used to test the significance
of correlations between the data obtained. A probability
value less than 0.05 was considered significant.
Results
[123I]IBZM measurements in vivo, ex vivo and in vitro
The MPS measurements of the distribution of [123I]IBZM
revealed a good discrimination of the different activities in
vivo. Moreover, the in vivo data showed a good correlation
with in vitro measurements.
Uptake of [123I]IBZM was observed for 3 h. Figure 1
presents transversal slices of the brain after application of
0.61 MBq/g [123I]IBZM (34 g body weight) in relation to
transversal MR images (36 g body weight). Figure 2 shows
transversal and sagittal slices of the brains at the four dose
levels during the fifth acquisition period.
The evaluation of uptake of [123I]IBZM by means of the
Vinci 2.3.1. processing tool shown in Fig. 3a was
performed using a volume-based approach as described
earlier [30]. Figure 3b presents the respective data obtained
by means of the InVivoScope processing tool. The
proportion between specific and non-specific binding
related to the total volume of the brain decreased from 1:5
to values > 1 at the 100th min of the observation period
(fifth acquisition period; data not shown). A comparison of
the data points obtained for the four doses (for each dose
mean value of all acquisition periods with exception of
period 2 and 6) using ANOVA followed by the Student-
Newman-Keuls post hoc test (Fig. 4a, b) reveals the range
in which the multi-pinhole system reflects differences in the
uptake of the receptor ligand under the experimental
condition described. Differences between the mean values
obtained using the Vinci 2.3.1. processing tool were
identified as significant upward from 20% of the uptake at
the maximal dose activities applied. The same uptake was
reflected with a 30% difference (610 kBq/g body weight
and 510 kBq/g body weight obtaining group) but with the
same probability of significance with the InVivoScope
processing tool. Figure 5 shows good correlations between
activity measurements of excised brains in vitro and the
intensity values observed in vivo (Fig. 5a) analysed by
means of the InVivoScope data processing tool. The border
of detection is indicated by interpolation of the regression
line to the x-axis (Fig. 5a) revealing 45 kBq as the smallest
activity accumulated in the whole brain under in vivo
conditions for appropriate visualisation of the striata
following application of [123I]IBZM. The SUV calculated
for all brains was SUV=0.36±0.016 giving a relative
standard deviation of 9% for the [123I]IBZM experiments
reflecting a variation coefficient in a range expectable for
an in vivo method for the determination of physiological
parameters applied to a small group of animals. InVivo-
Scope data obtained in the striata in vivo and their
correlation with the respective data points determined by
means of the Vinci processing tool are shown for the third
Fig. 1 MR and [123I]IBZM
SPECT images of murine brains.
a Transversal MR images were
obtained with an echo time of TE
14 ms and a repetition time of TR
2,000 ms. Measurement was per-
formed using a field of view of
32×19.2 mm and a matrix of
512×256. Slices of 0.7 mm
thickness were scanned with
0.7-mm gaps between the regis-
tered planes. b Transversal multi-
pinhole SPECT images of a brain
obtained following processing by
means of Vinci 2.3.1; 0.61 MBq
[123I]IBZM/g body weight were
applied. SPECT measurement
was performed using acquisition
times of 100 s and 10 steps of
rotation. 1 position of the harder-
ian glands, 2 position of the
striata
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acquisition period (Fig. 5b) and for the eighth acquisition
period (Fig. 5c).
The activities applied in the present experiments were in
accordance with the range proposed by the modified
Goertzen equation [4, 30]. Moreover, Eq. 1 allows a simple
estimation of the activity necessary for equivalent visual-
isation of [123I]IBZM binding (or ligands with similar
cerebral uptake behaviour) to striata in different species
with different brain and body weights.
A2 ¼ D1  BRwt1  BDwt2
BRwt2
ð1Þ
A2 activity to apply to the animal of the second
species
D1 tissue uptake in species 1 corresponding to the
desired visualisation level
Fig. 3 Time course of striatal uptake of [123I]IBZM. Uptake of [123I]
IBZM is shown after application of 0.44, 0.56, 0.61 and 0.95 MBq/g
body weight in mice. Imaging conditions were used as described in
the legend of Fig. 2. The numbers of the x-axis correspond to the
consecutive acquisition periods 1 to 8. a Time course analysed using
the Vinci 2.3.1. processing tool. b Time course analysed using the
InVivoScope processing tool
Fig. 4 [123I]IBZM uptake into murine striata. Mean ± SEM was
calculated for each animal from 12 data points (right and left striata)
involving six acquisition periods, when the complete set of intensity
data at the four activity doses was available. *p<0.05 vs 950 kBq/g
body weight. #p<0.05 vs 610 kBq/g body weight. ANOVA followed
by the Student-Newman-Keuls test was used for statistical compari-
son. See Fig. 2 for further description of the imaging conditions
Fig. 2 Transversal and sagittal
slices of murine brains with
different uptake of [123I]IBZM.
Brains of four mice are shown
following application of 0.95 (a),
0.61 (b), 0.56 (c) and 0.44 (d)
MBq/g during the fifth acquisi-
tion period (A transversal slices,
B sagittal slices). MPS was per-
formed using acquisition times of
100 s per scan, 10 steps of
rotation and a radius of rotation
of 37 mm. Body weights of the
mice were 42 g (a), 34 g (b),
34 g (c) and 50 g (d). Maximum
intensity projections of a have
been shown in [30]
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BRwt1 brain weight of first species
BRwt2 brain weight of second species
BDwt2 body weight of second species
Figure 6 shows these activities for different proportions
of brain and body weights suggesting that an equivalent
visualisation as in a 30-g mouse can be obtained in a rat of
300 g body weight, using only the 2–2.5-fold of the activity
applied in mice although the proportion of the body weights
is 1:10. This calculation however does not include the
potential influence of further aspects such as species
differences in distribution velocity of the tracers as
described previously [33] or species differences in metab-
olism or carrier kinetics.
Figure 7 shows [99mTc]HMPAO SPECT images. The
tracer allows a visualisation of brain perfusion using an
activity of 1.16 MBq/g even at an acquisition time of 140 s
but not using half of that activity (for maximum intensity
projections of [123I]IBZM and [99mTc]HMPAO SPECT see
Supplement 1A and Supplement 1B, respectively).
Cardiac uptake of [99mTc]sestamibi and [123I]IPPA
MPS images of the distribution of [123I]IPPA are shown in
a wild-type mouse during the first 57 min p.i. in Fig. 8.
The heart weights of the transgenic animals were
enhanced to 193.6±14.2 mg vs 112.6±8.25 mg in wild-
type mice, while the body weights were 22.8±1.46 g and
24±1.66 g, respectively. The cardiac uptake of [99mTc]
sestamibi measured in vitro by means of the activimeter
was 6.2±0.78 in transgenic and 8.3±0.99 kBq/mg in wild-
type animals. The SPECT imaging method reflected the
alterations in cardiac anatomy as well as the enlargement of
the right ventricles in cardiomyopathic hearts found also by
means of MR imaging (Fig. 9).
The visualisation of [99mTc]sestamibi in the heart
required 4–10-fold higher doses than for the 123I-labelled
receptor ligands. Figure 10 shows a comparison between
two hearts after application of the same activity (3.8 MBq/g
Fig. 6 Approach to estimation of activities for equipotent visual-
isation of 123I-labelled receptor ligands in different species according
to Eq. 1. The figure shows activities proposed for the application to
different species to obtain a visualisation equipotent to that observed
in mice. The numbers 1 to 6 of the x-axis correspond to the conditions
listed in the table below the diagram. BRwt1 brain weight of the first
species, BRwt2 brain weight of the second species, BDwt2 body
weight of the second species. The lines connect the doses per animal
resulting in visualisation levels (v) corresponding to the visualisation
quality expected in mice following application of 0.5 MBq [123I]
IBZM/g body weight (v1), 1 MBq/g body weight (v2), 2 MBq/g body
weight (v3) and 3 MBq/g body weight (v4)
Fig. 5 In vitro uptake of [123I]IBZM versus in vivo imaging data
obtained with different processing tools. a Correlation between striatal
uptake of [123I]IBZM in vivo analysed using the InVivoScope
processing tool with the total cerebral activities observed. In vivo
data reflect the activity detected in right and left striata of the four
animals analysed also in Figs. 2–4. Conditions of the measurements
are in accordance with that described in the legend of Fig. 2. The
offset for y (in vivo intensity) =0 was determined as x0 45 kBq and
regarded as the border of detection under the acquisition conditions
chosen (100 s acquisition time and 10 steps of rotation). Higher
acquisition times should diminish the detection threshold. b, c
Correlation between data of striatal accumulation of [123I]IBZM
obtained using the Vinci 2.3.1. and InVivoScope processing tools
during acquisition periods 3 (b) and 8 (c). Right and left striata of four
animals were involved in the calculations
1500 Eur J Nucl Med Mol Imaging (2009) 36:1495–1509
body weight; for maximum intensity projections see
Supplement 2A and Supplement 2B). Figure 11 shows
real-time yield as kcps per detector and the respective
intensity values registered within the total field of view of
measurement evaluated by means of the InVivoScope
processing tool (periods 1 and 2 in vivo as well as four
hearts ex vivo). The high yield in the range of 3–14 kcps/
detector during the in vivo measurements (in comparison to
Fig. 7 Uptake of [99mTc]
HMPAO in the murine brain.
[99mTc]HMPAO uptake after ap-
plication of 0.47 (A) and
1.16 MBq/g body weight (B).
The body weight of the animals
was 36 g. Acquisition time of
140 s and 10 steps of rotation
were used for imaging. 1 thyroid
gland, 2 salivary gland, 3 lacri-
mal gland and ducts. Planes of
the sections: a coronal, b trans-
versal, c sagittal. Sections Aa
and Ba were measured at prone
position of the animals, however,
are shown here in supine position
Fig. 8 Multi-pinhole SPECT of
murine heart (wild-type) after
application of [123I]IPPA.
Images were obtained using the
Vinci 2.3.1. processing tool
during three consecutive acqui-
sition periods following appli-
cation of 0.89 MBq/g [123I]IPPA
into a B6C3F1(EP3) wild-type
mouse with 22 g body weight.
a Short axis view. b Horizontal
long axis view. c Vertical long
axis view. 1 liver, 2 heart
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0.5-2 kcps in the [123I]IBZM brain experiments) is
predominantly due to the higher total dose activity applied
in the [99mTc]sestamibi experiments. Additionally, a good
correlation between in vitro data and in vivo measurements
was found for the assessment of the [99mTc]sestamibi using
the InVivoScope data processing tool, while data obtained
by means of the Vinci 2.3.1. processing tool using only the
intensities measured in the left ventricle in vivo showed a
lower correlation coefficient (Fig. 12).
The in vitro investigation of hearts from cardiomyo-
pathic and wild-type littermates as well as the uptake of
[99mTc]sestamibi observed during SPECT imaging revealed
a 30% reduction of the cardiac perfusion (Fig. 13). The
SUV were calculated referring to the percentage of the
activity localised in the heart (InVivoScope, Fig. 12a) to 1%
of the body weight [25, 26]. Further evaluation of the
intracardiac uptake of [99mTc]sestamibi was performed
analysing ROIs as depicted in Fig. 14. Both transgenic
and wild-type mice showed a heterogeneous uptake of
[99mTc]sestamibi with the lowest values in the apical region
and right ventricle. A markedly lower fraction of [99mTc]
sestamibi was found in the septal apical as well as in the
lateral basal and apical regions in transgenic hearts
compared to wild-type hearts.
Fig. 9 MR and SPECT images
of cardiomyopathic and wild-
type hearts. a–d Short axis view
of end-diastolic (a and c) and
end-systolic hearts (b and d) of
B6C3F1-Tg(EP3) mouse (a and
b) and a wild-type littermate (c
and d). e, f Short axis view of a
cardiomyopathic (e) and wild-
type (f) heart labelled with
[99mTc]sestamibi. g, h Short axis
view of a cardiomyopathic (g)
and a wild-type (h) heart la-
belled with [123I]IPPA
Fig. 10 Images of cardiomyo-
pathic and wild-type hearts:
short axis and horizontal and
vertical long axis views after
application of [99mTc]sestamibi.
a A cardiomyopathic heart with
cardiac overexpression of the
EP3 receptor. Body weight of
the mouse was 22 g and heart
weight 187 mg. SA short axis
view, HLA horizontal long
axis view, VLA vertical long axis
view. b A wild-type mouse with
a body weight of 24 g and
138 mg heart weight. Measure-
ments were performed using
150 s acquisition time and 10
steps of rotation after applica-
tion of 3.8 MBq/g body weight
[99mTc]sestamibi
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Discussion
The present study provides a first direct quantitative
comparison of volume-based evaluation of in vivo imaging
data and in vitro data on the uptake of SPECT tracers in
murine brain and heart using [123I]IBZM and [99mTc]
sestamibi, respectively. Thresholds of detection are calcu-
lated for tracers with different distribution patterns in
murine brain and in the heart, respectively, for the
conditions of the multi-pinhole SPECT system employed.
Moreover it is shown that the multi-pinhole SPECT method
is able to identify differences in the range of 20% of the
maximal uptake in the dose range between 950 kBq/g and
440 kBq/g employed in this study. The in vivo uptake of
[123I]IPPA in mice is visualised for the first time.
Brain investigations
Dopamine D2 receptor ligands such as [
123I]IBZM or [11C]
raclopride belong to the preferred tools used to investigate
the performance of small animal SPECT and PET imaging
devices with respect to in vivo visualisation of brain
structures and signal transduction [26–28, 30]. That is due
to the fact that dopamine D2 receptors are found with a high
density in the striatum as a compactly shaped telencephalic
part of the brain, providing a well-defined volume of
interest ranging from 30 to 60 mg (both striata in summary)
in adult mice surrounded by a large zone of lower
dopamine D2 receptor density and relatively low non-
specific binding.
Evaluations of PET and SPECT in vivo imaging data in
small animal models with the aim of developing algorithms
for tracer quantification or coregistration with other
imaging data have been described previously [24, 36–40].
The literature includes comparisons with autoradiographic
measurements or other semi-quantitative reference tissue
methods for brain, heart and some tumour models of
different localisations [39, 41]. In our MPS [123I]IBZM
measurements, the activity bound non-specifically in the
whole brain decreases at the end of the observation period
of 3 hs to 20% of the initial values, while the activity bound
specifically reached an equilibrium during the fifth acqui-
sition period. This is in agreement with the time course
reported in a previous pinhole SPECT study of [123I]IBZM
in mouse models [28] as well as with an ex vivo study [40].
The imaging data evaluated with the InVivoScope and
Vinci 2.3.1. data processing tools allowed us to distinguish
differences upwards from 20% of maximal tracer amount
accumulated in the brains in the dose range between
440 kBq/g and 950 kBq/g. The least-squares linear fit for
the comparison of in vitro and in vivo uptake of [123I]IBZM
allowed us to reveal that this percentage corresponds to a
total cerebral activity of 116 kBq/g. The estimate involves
the assumption that approximately 50% of the tracer
detected in the brain binds to receptors in the striata. A
lower ratio of striatal to total cerebral activity would result
in higher activity values.
There are only a few reports on measurements of [123I]
IBZM in the murine brain using SPECT or multi-pinhole
SPECT, respectively. More attention has been paid to
ligands of dopamine transporters using [123I]FP-CIT or
Fig. 12 Correlation of cardiac accumulation of [99mTc]sestamibi in
vitro and in vivo. a Comparison of in vivo data obtained using the
InVivoScope data processing tool with in vitro activities in transgenic
and wild-type animals. b Comparison of in vivo data obtained using
the Vinci 2.3.1. data processing tool with in vitro activities in
transgenic and wild-type animals
Fig. 11 Yield obtained per detector during measurements of cardiac
uptake of [99mTc]sestamibi. Data of 14 mean values of measurements in
phase 1 and phase 2 and data of four ex vivo heart measurements (the
four lowest values depicted) are correlated with arbitrary units obtained
using the InVivoScope data processing tool. Kcps reflecting the average
of counts displayed on the screen during all acquisition periods (150 s
and 10 steps of rotation) are correlated with the results of the evaluation
by means of the InVivoScope data processing tool. The regression line
demonstrates the linearity of the multi-pinhole device
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99mTc-labelled ligands such as [99mTc]TRODAT [25, 30,
39, 42, 46]. This may be due to the fact that the preparation
of [123I]FP-CIT, which is commercially available, contains
less ethanol than preparations of [123I]IBZM on the one
hand and shows higher specific activity on the other hand.
This allows easier i.v. application and promises a favour-
able proportion of occupancy of the target structures at
appropriate visualisation quality. A direct comparison of in
Fig. 13 SUV in B6C3F1-Tg(EP3) and wild-type mice in vitro and in
vivo. Comparison of [99mTc]sestamibi uptake in the heart: in vitro (a)
and in vivo (b). [99mTc]sestamibi accumulations in five B6C3F1-Tg
(EP3) mice and their wild-type littermates were used for calculation of
cardiac SUV. Means ± SEM are shown. Asterisks indicate p<0.005
calculated for the two-tailed paired Student’s t test. Calculation of
standard uptake in vitro was performed using activities and weights
determined in excised hearts. Calculation of in vivo data was
performed using activities determined using the regression line in
Fig. 12a referring to the apparent heart volume calculated by the
InVivoScope tool. SUV in vitro is given without dimension and SUV
in vivo has the dimension arbitrary units (InVivoScope)/MBq
Fig. 14 Comparison of regional
cardiac accumulation of [99mTc]
sestamibi in cardiomyopathic
and wild-type mice. a Horizon-
tal long axis view. b Vertical
long axis view. ROI: 1 lateral
basal, 2 lateral apical, 3 apical, 4
septal apical, 5 septal basal, 6
right ventricle, 7 anterior basal,
8 anterior apical, 9 apical, 10
inferior apical, 11 inferior basal.
Means ± SEM are shown.
Asterisks indicate differences
between the respective ROIs
between cardiomyopathic hearts
and the hearts of the wild-type
littermates with p<0.05; 5–11
data points observed in the
acquisition periods 1–3 were
used for the calculation of each
mean value
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vitro and in vivo measurements in murine models (or other
rodents) neither exists for [123I]IBZM nor for dopamine D2
receptors labelled with positron-emitting isotopes. The
fraction of the total cerebral [123I]IBZM found in the striata
during our experiments was calculated for the different
observation times to be in the range between 25 and 50%.
Studies analysing ligand binding following chemical
impairment of the target region or with displacement by
highly specific antagonists of receptors or transporters
describe alterations in the receptor occupancy of 50–90%
[27, 43]. Chalon et al. reported in 1990 [43] for in vivo/ex
vivo studies using [125I]IBZM a 45% increase of the binding
of the tracer after pre-treatment with haloperidol. Singhaniyom
et al. [44] observed a displacement of [125I]IBZM by about
72% following in vivo pre-treatment with antagonists of the
dopamine D2 receptor in mice. Under such conditions multi-
pinhole SPECT already provides a suitable tool for in vivo
characterisation of signal transduction units.
Using the InVivoScope data processing tool, we found
4.2±0.27 of the injected dose of [123II]BZM per g brain
tissue. For an activity of 109 kBq/brain as measured in one
of our experiments at a specific activity of 74 TBq/mmol
and 50% of total cerebral activity in the striata (30 mg wet
weight), 24.5 nmol/kg [123I]IBZM are bound. That would
be close to half of the Bmax value in vitro but below the
ED50 described for IBZM previously with 37 nM [47, 48].
The receptor occupancy calculated according to the
equation given by Hume et al. [23] with occupancy ¼
activity  weight  ED50  specific activityþ activity was
18.5±2.5% for all [123I]IBZM experiments (range: 25–
13%). This confirms our previous estimation using prelim-
inary SPECT data of [123I]IBZM uptake and the assumption
that at activities of ≤20 MBq/animal (in mice weighing 50–
25 g) the concentration of IBZM stays below ED50, but for
displacement studies with a low mass effect it is necessary to
work with higher specific activities than the reference 74
TBq/mmol used in our calculations [30]. This reference is
the lower boundary of the specific activity guaranteed by the
manufacturer. The concentration in non-striatal cerebral
tissue in the sample described above was 1.62 nmol/kg at
the same time resulting in a ratio of specific to non-specific
binding of 15. Meyer et al. [40] described a ratio of 17 in
autoradiographic studies in mice if working with a ketamine/
xylazine (without isofluorane) anaesthesia comparable to that
which we applied. The ratio was markedly lower if
isoflurane was included in the anaesthesia. An occupancy
below 5% can be achieved with higher specific activities as
described recently [42].
The dose-dependent increase in the uptake of [123I]
IBZM during the eight observation periods suggests that the
activity doses applied are in the linear range of the dose-
response curve. This allowed identification of the border of
detection for the difference in the uptake in regard to
different injection doses without impairment by saturation
effects.
The activity threshold for the visualisation of in vivo
uptake in the brain for a tracer like [123I]IBZM with a small
target region and a relatively high specific activity was
45 kBq (and 6 kBq ex vivo; data not shown; using 100 s
acquisition time and 10 step rotation mode in our camera
system) as revealed by the offset of the regression line for
the comparison between in vivo and in vitro data at y=0.
The comparison of the doses recommended to be applied in
different species for several visualisation levels is verified
for ligands of dopamine transporters and receptors in mice
and rats by our own data. The results agree also with the
calculations by Kung et al. [47, 48]. If measurements of
species with larger geometric dimensions require a larger
radius of rotation further correction factors are necessary.
Weber et al. [49] described for a triple-headed pinhole
SPECT system how spatial resolution and sensitivity
change with the increase in the distance between detectors
and target region. Taking these alterations into account for a
special multi-pinhole system, also the doses necessary for
equipotent visualisation would need an additional correc-
tion factor. An increased role of attenuation in larger
species would also require further modification of the data
[41]. For a tracer such as [99mTc]HMPAO with homoge-
neous distribution through the target organ as well as a
specific activity<5% [50] of that of the receptor ligand
investigated in our study, the threshold of detection is 2–10-
fold higher.
[99mTc]HMPAO ([99mTc]exametazime [(RR, SS])-4,8-
diaza-3,6,6,9-tetramethylundecane-2,10-dione bisoxime) is
an uncharged, low molecular weight, lipophilic complex
that easily crosses the blood-brain barrier [51]. It is known
that in man 3–5 to 7% of HMPAO injected pass into the
brain by passive diffusion during the first minutes after
injection. In humans it remains for 24 h in the brain,
probably trapped inside cells via a reaction with glutathione
[52], and is not preferentially bound to a specific region of
the brain.
Cardiac investigations
Altered activity requirements were also revealed during the
imaging of the perfusion tracer [99mTc]sestamibi (4–10-fold
of that necessary for the [123I]IBZM experiments). The
lipophilic compound [99mTc]sestamibi is a cationic complex
which is accumulated in tissues rich in mitochondria like
liver and heart and trapped in the mitochondrial matrix
[53]. Accumulations of 1.2% of the dose were reported for
silent myocardium and 1.5% under stress [51]. The
compound enters the heart by passive diffusion and
correlates well with regional perfusion under conditions of
normal load. It shows almost no redistribution [54] under
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these conditions, while its extraction at high coronary flow
or under hypoxic conditions is not proportional to coronary
perfusion [51].
Our model of cardiac overexpression of the EP3 receptor,
a subtype of the prostaglandin receptor, showed a decreased
cardiac accumulation of [99mTc]sestamibi in the transgenic
animals compared to their wild-type littermates. This
suggests a contribution of disturbances in perfusion or
mitochondrial dysfunction [55] to potential changes in the
uptake of metabolic tracers—in our case the long chain
fatty acid [123I]IPPA [14, 56].
Quantitative comparison of in vitro and in vivo uptake of
[99mTc]sestamibi in murine hearts observed with SPECT
cameras is not available in the literature to our knowledge.
However, semi-quantitative approaches have been reported
by Zhou et al. [57] for investigations of [99mTc]sestamibi-
labelled regionally ischaemic rat hearts included in dual
isotope studies (140 and 247 keV) on the tracking of
[111In]-labelled stem cells [41, 57]. Zhou et al. employed a
triple-headed pinhole camera for the detection of [99mTc]
sestamibi (74 MBq/animal) and could show the grafting of
the stem cells during a 96-h observation period. A bull’s
eye plot was used for the evaluation of regional cardiac
distribution of 99mTc and 111In. Left ventricular visual-
isation of the tracers was obtained in a similar quality as in
our experiments. Beekman et al. [58] were able to visualise
murine heart perfusion with a submillimetre resolution after
injection of 222 MBq [99mTc]tetrofosmin. However, quan-
titative approaches to the correlation of in vivo SPECT data
with in vitro measurements of the tracer uptake are rather
available for sestamibi and other perfusion tracers in
porcine and canine models [59, 60]. Da Silva et al. [60]
drew an offset of 7–11 kBq/g heart weight from the
correlation of in vivo SPECT data of [99mTc]sestamibi
uptake in porcine hearts with ex vivo data. That would give
a detection threshold of 1 MBq total uptake for a 150-g
heart. For our murine hearts in the multi-pinhole system we
found a threshold of 200 kBq/heart. That corresponds for
hearts with a size between 100 and 200 mg to 1–2 MBq/g.
Compared to the offset found in the porcine model the
threshold for the uptake per murine heart would be lower,
but the offset per g heart weight would be 150–350-fold
higher. However, the ratio of the body weights of mouse
and pig would be 1:1,000.
Estimates of the whole-body dose in SPECT [61] are
given with a range from less than 2 cGy (160 MBq of
99mTc; biological half-life 1 h) in rats to 90 cGy (740 MBq
in 30 g-mice assuming a residence time of 3.2 h) [41]. The
activity of [99mTc]sestamibi applied in our experiment
comprised maximally 30% of this amount and on average
15%. Funk et al. [61] reported theoretical values of the
whole-body doses from phantom measurements
corresponding to the conditions of biological experiments
in the range between 6 and 90 cGy for mice and 1–27 cGy
for rats and a LD50 of 7 Gy/30 d for mice.
Transgenic B6C3F1(EP3) mice show an increase of left
ventricular mass, end-diastolic and end-systolic volumes as
well as a significant decrease in left ventricular ejection
fraction and dP/dt, as found recently [29]. These alterations
were already obvious in 5- to 7-week-old animals [29]. Our
data support the maintenance of the cardiomyopathic
alterations in the 11- to 17-week-old mice with 8.6±
0.36 mg heart weight/g body weight in comparison to
4.6±0.14 mg/g in wild-type littermates.
The analysis of the hearts excised in transgenic and wild-
type littermates following the SPECT measurements
revealed that the uptake of [99mTc]sestamibi was 30% lower
in cardiomyopathic animals than in wild-type animals. This
difference is confirmed if the SUV is calculated for in vivo
conditions. The segmental analysis of ROIs reveals hetero-
geneity of [99mTc]sestamibi accumulation in both cardio-
myopathic and wild-type hearts with lowest uptake in the
apical regions, but reduced accumulation of [99mTc]sesta-
mibi in the septal and lateral part of the left ventricle of
transgenic mice compared to the wild-type animals.
[123I]IPPA, in contrast to [99mTc]sestamibi or [99mTc]
HMPAO, is accumulated in the target tissue achieving 39%
of the injected dose per g heart weight [56] by an active
process via a CD36 protein acting as a carrier of long chain
fatty acids [14, 62]. It is not clear whether the paradoxical
hypertrophic response of the heart to the overexpression of
EP3 receptors, which are known to mediate cardiac
protection, is related to these processes. Although an
increased phosphorylation of the S6 ribosomal protein has
been observed, and it is known to correlate with an
enhanced protein synthesis, the kind of relation between
EP3 overexpression and morphological and metabolic
alterations associated with the cardiomyopathic properties
of these hearts has not been characterised. In contrast,
alterations in the parameters of contractility and cardiac
function can be explained by mediation by the known
signalling pathways via Gi-coupled receptors. The imaging
of the uptake of long chain fatty acids by MPS methods
provides the possibility to investigate such regulatory
processes and their metabolic consequences in vivo.
The present investigations support the theory that the
multi-pinhole SPECT device in combination with suitable
data processing tools is capable of visualising such
alterations and quantifying metabolic processes and ligand
binding in different target organs of mice in a feasible dose
range. Recently, the quantitative approach which can be
used in experimental models has received further support
by a plenitude of reports concerning attenuation [63],
algorithms for improving reconstruction image quality
[64, 65], further improvement of the pinhole collimator
design [66, 67] and multimodal approaches used for PET
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and SPECT investigations [36, 68]. The small scale of
murine models is not only a disadvantage for visualisation,
but also offers advantages for example in relation to the
attenuation [41]. The multi-pinhole approach in contrast to
small animal PET allows multi-isotope investigations and
provides advantages by a more favourable whole-body dose
during the use of SPECT isotopes in comparison to positron
emitters, shown by favourable MIRD S values [61],
availability of SPECT isotopes and high specific activity
for receptor and transporter ligands exceeding frequently
those of PET radiopharmaceuticals. The rising availability
of CT/SPECT as well as the use of a gated mode of
measurements during cardiac investigations extend the
access to in vivo information on biochemistry, molecular
and cell biology as well as physiology.
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